Gaucher Disease News and Research

RSS
Genzyme marks 2013 International Rare Disease Day

Genzyme marks 2013 International Rare Disease Day

Positive new data from Genzyme’s eliglustat tartrate Phase 3 studies on Gaucher disease type 1

Positive new data from Genzyme’s eliglustat tartrate Phase 3 studies on Gaucher disease type 1

Maryland scientists create stem cell model for Gaucher disease

Maryland scientists create stem cell model for Gaucher disease

FDA approves Protalix, Pfizer’s ELELYSO for treatment of type 1 Gaucher disease

FDA approves Protalix, Pfizer’s ELELYSO for treatment of type 1 Gaucher disease

Pfizer receives FDA approval for Elelyso to treat Type 1 Gaucher disease

Pfizer receives FDA approval for Elelyso to treat Type 1 Gaucher disease

Genzyme announces four-year data from eliglustat tartrate phase 2 trial on Gaucher disease type 1

Genzyme announces four-year data from eliglustat tartrate phase 2 trial on Gaucher disease type 1

Lixte's LB-205 shows therapeutic potential against Gaucher disease

Lixte's LB-205 shows therapeutic potential against Gaucher disease

PDUFA goal date of NDA for Protalix's taliglucerase alfa extended

PDUFA goal date of NDA for Protalix's taliglucerase alfa extended

FDA accepts Protalix taliglucerase alfa NDA resubmission for review

FDA accepts Protalix taliglucerase alfa NDA resubmission for review

Blood stored in banks may undergo changes and damage

Blood stored in banks may undergo changes and damage

New insight into Parkinson's disease

New insight into Parkinson's disease

Shire's Replagal and VPRIV data on Gaucher and Fabry patients presented at ACMG meeting

Shire's Replagal and VPRIV data on Gaucher and Fabry patients presented at ACMG meeting

Protalix receives FDA CRL for taliglucerase alfa NDA for Gaucher disease

Protalix receives FDA CRL for taliglucerase alfa NDA for Gaucher disease

Protalix: New data from taliglucerase alfa, oral GCD trials to be presented at Lysosomal Disease Network Symposium

Protalix: New data from taliglucerase alfa, oral GCD trials to be presented at Lysosomal Disease Network Symposium

Genzyme reports 3-year follow-up data from eliglustat tartrate Phase 2 trial for Gaucher disease

Genzyme reports 3-year follow-up data from eliglustat tartrate Phase 2 trial for Gaucher disease

Genzyme's diagnostic products sold to Sekisui Chemical for $265 million

Genzyme's diagnostic products sold to Sekisui Chemical for $265 million

Genzyme to expand Geel facility to support growth of Myozyme and Lumizyme for Pompe disease

Genzyme to expand Geel facility to support growth of Myozyme and Lumizyme for Pompe disease

Health Canada approves VPRIV enzyme replacement therapy for type 1 Gaucher disease

Health Canada approves VPRIV enzyme replacement therapy for type 1 Gaucher disease

Pfizer, Protalix announce marketing authorization submission in Europe for taliglucerase alfa

Pfizer, Protalix announce marketing authorization submission in Europe for taliglucerase alfa

Positive preliminary data from Protalix's taliglucerase alfa switchover trial for Gaucher disease

Positive preliminary data from Protalix's taliglucerase alfa switchover trial for Gaucher disease